secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2023-05-25T23:59:59+00:00
Accession:  0001213900-23-043101
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Therapeutics stockholders approve plan amendment and elect directors
----------------------------------------------------------------------------

- Stockholders approved amendment to 2021 Equity Incentive Plan, increasing authorized shares by 2,500,000 to 7,900,000.
- Charles J. Casamento and Sergio Traversa elected as Class II directors with 10,159,479 and 17,003,403 votes respectively.
- Ratification of Marcum LLP as independent auditor for fiscal 2023 approved with 22,048,083 votes.
- Approximately 76.9% of eligible common stock voted at the annual meeting held on May 25, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023043101/0001213900-23-043101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023043101/ea179287-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-043101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer